Safety Alert: OmniPod Needle Mechanism Failure

A problem has been found in certain lots of OmniPod distributed in the U.S. and internationally. This failure may cause elevated blood glucose (hyperglycemia) which, if left untreated, can result in diabetic ketoacidosis (DKA).

Insulet Corporation initiated a lot-specific voluntary Field Safety Notification for 15 lots of the OmniPod (Pod) which were distributed in the U.S. and three lots which were distributed internationally for use by people living with diabetes.

OmniPod Safety Notice
Problem may cause elevated blood glucose (hyperglycemia)

Insulet has notified its distributors and customers by email, FedEx, and phone calls beginning on November 2, 2015, as well as all applicable regulatory agencies, including U.S. Food and Drug Administration (FDA). Consumers with questions may contact Insulet Customer Care via telephone at 1-855-407-3729 at any time.

This Notification is due to a slight increase in the reported cases in which the Pod’s needle mechanism failed to deploy or there was a delay in the deployment of the needle mechanism.

The reported incidence of this product issue in the affected lots is approximately 1%-2%. Once this issue was recognized, the Company corrected the manufacturing process and implemented additional inspection steps.

Continue Reading Below ↓↓

This Notification does not affect the OmniPod Personal Diabetes Manager (PDM).

In the event a needle mechanism fails to deploy, the needle will not be inserted and insulin delivery will not begin. The interruption of insulin delivery may cause elevated blood glucose (hyperglycemia), which, if left untreated, can result in diabetic ketoacidosis (DKA). If a patient has activated a Pod and experiences unexpected elevated blood glucose levels, a healthcare professional should be consulted.

The affected Pod lots have resulted in 66 Medical Device Reports, of which three required medical intervention. No serious injuries or deaths have been reported in patients using OmniPod devices from the affected lots.

Consumers who have Pods from the affected lots should ensure the needle mechanism has deployed properly, and may contact Insulet Customer Care via telephone at 1-855-407-3729 at any time.

OmniPods from the affected lots listed below were distributed to customers in September 2015:

DistributionCatalog NumberDescriptionLot Number
United StatesPOD-ZXP420OmniPod®, Insulin Management SystemL41880
L41881
L41892
L41895
L41897
L41898
L41899
L41900
L41901
L41902
L41903
L41904
L41905
L41906
L41907
International14810OmniPod®, Insulin Management SystemL41908
L41910
F41935

Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA’s MedWatch Adverse Event Reporting program
Source: FDA

LEAVE A REPLY

Please enter your comment!
Please enter your name here